Kingdom Capital Advisors, a private investment firm, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. Kingdom Capital Advisors is in its third year of operation as of the end of 2024. Since the firm’s inception, small cap stocks, as determined by the Russell 2000 TR, have experienced a cumulative return of roughly 7%, while KCA has experienced an 89% return. The strategy returned 2.07% (net of fees) in the fourth quarter compared to 0.33%, 2.41%, and 4.93% returns for the Russell 2000 TR, S&P 500 Index TR, and the NASDAQ 100 TR, respectively. In addition, please check the fund’s top five holdings to know its best picks in 2024.

In its fourth quarter 2024 investor letter, Kingdom Capital Advisors emphasized stocks such as Enzo Biochem, Inc. (NYSE:ENZ). Headquartered in Farmingdale, New York, Enzo Biochem, Inc. (NYSE:ENZ) is a life sciences company. One-month return of Enzo Biochem, Inc. (NYSE:ENZ) was -3.24%, and its shares lost 61.11% of their value over the last 52 weeks. On March 21, 2025, Enzo Biochem, Inc. (NYSE:ENZ) stock closed at $0.4861 per share with a market capitalization of $25.396 million.

Kingdom Capital Advisors stated the following regarding Enzo Biochem, Inc. (NYSE:ENZ) in its Q4 2024 investor letter:

Our top contributors to Q4 returns were United Natural Foods (UNFI) and National Presto Industries (NPK), while Superior Industries (SUP) and Enzo Biochem, Inc. (NYSE:ENZ) were our largest detractors. Enzo Biochem also declined significantly in December after their FYQ1 revenue decreased 20%. Enzo now trades for less than the cash on their balance sheet ($38m market cap versus >$40m of cash). We expect their eventual liquidation will produce upside; however, the revenue decline in their business significantly reduces the potential proceeds. Recent legal developments suggest the final barriers to liquidation are being removed, but the shareholder base appears exhausted from continued disappointments.

A microbiologist in a lab coat examining a petri dish through a microscope.

Enzo Biochem, Inc. (NYSE:ENZ) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 7 hedge fund portfolios held Enzo Biochem, Inc. (NYSE:ENZ) at the end of the fourth quarter which was 5 in the previous quarter. While we acknowledge the potential of Enzo Biochem, Inc. (NYSE:ENZ) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.